Morgan Stanley’s Metagenomi Therapeutics MGX Stock Holding History

Morgan Stanley’s Portfolio MGX Stock Details MGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.31K	Sell	5,302 -22,264	-81%	-$29.8K	﹤0.01%	7155
2026 Q1	$36.9K	Sell	27,566 -32,116	-54%	-$49.9K	﹤0.01%	6528
2025 Q4	$96.7K	Sell	59,682 -181,652	-75%	-$393K	﹤0.01%	6219
2025 Q3	$572K	Sell	241,334 -8,853	-4%	-$18K	﹤0.01%	5445
2025 Q2	$370K	Buy	250,187 +56,434	+29%	+$88.4K	﹤0.01%	5600
2025 Q1	$264K	Sell	193,753 -582,033	-75%	-$1.39M	﹤0.01%	5619
2024 Q4	$2.8M	Buy	775,786 +711,149	+1,100%	+$1.72M	﹤0.01%	4452
2024 Q3	$140K	Buy	64,637 +19,919	+45%	+$69.1K	﹤0.01%	5875
2024 Q2	$182K	Buy	44,718 +35,513	+386%	+$244K	﹤0.01%	5725
2024 Q1	$97.1K	Buy	+9,205	New	+$106K	﹤0.01%	6005

Other funds holding MGX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PVI

Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley's MGX Position: Q2 2026 in Review

Morgan Stanley reduced its Metagenomi Therapeutics (MGX) stake by 81% in Q2 2026, selling an estimated $29.8K and leaving 5,302 shares worth $6.31K. The position accounts for ﹤0.01% of the portfolio, ranked #7155.

Morgan Stanley first reported a position in MGX in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.8M in Q4 2024. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

Morgan Stanley held 5,302 shares of Metagenomi Therapeutics worth $6.31K as of Q2 2026.
Morgan Stanley sold 22,264 Metagenomi Therapeutics shares in Q2 2026, an estimated $29.8K.
Metagenomi Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #7155 holding.
Morgan Stanley first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 10 quarters since.
Morgan Stanley's Metagenomi Therapeutics position peaked at $2.8M in Q4 2024.
43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.